We are live on
!
Find out more
Lineage Cell Therapeutics
LCTX
LCTX
69 hedge funds and large institutions have $152M invested in Lineage Cell Therapeutics in 2015 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 12 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
439% more call options, than puts
Call options by funds: $2.58M | Put options by funds: $478K
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
83% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 12
33% more capital invested
Capital invested by funds: $114M → $152M (+$37.9M)
17% more funds holding
Funds holding: 59 → 69 (+10)
0.07% more ownership
Funds ownership: 45.47% → 45.54% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Holders
69
Holders Change
+10
Holders Change %
+16.95%
% of All Funds
1.84%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
14
Increased
22
Reduced
12
Closed
4
Calls
$2.58M
Puts
$478K
Net Calls
+$2.1M
Net Calls Change
+$2.23M
Top Buyers
Top Sellers
| 1 |
DWM
Destination Wealth Management
Walnut Creek,
California
|
-$2.22M |
| 2 |
Morgan Stanley
New York
|
-$283K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$159K |
| 4 |
SCP
Seizert Capital Partners
Birmingham,
Michigan
|
-$73K |
| 5 |
Bank of New York Mellon
New York
|
-$48.6K |
